Back to the Future: Can Vaccines Win the Long-Term Fight Against COVID-19?

por Ertl, Hildegund C. J., Currie, Sue L., Livermore, David M.
Publicado 2022

Restricting use of adenovirus vector-based COVID vaccines could endanger public and global health

por Ertl, Hildegund C. J., Currie, Sue L., Luber, Andrew D.
Publicado 2022

2320. Novel checkpoint modifier lowers T cell activation threshold and enhances and broadens vaccine-induced responses to chronic viral infections

por Hasanpourghadi, Mohadeseh, Luber, Andrew, Currie, Sue, Magowan, Colin, Zhou, Xiangyang, Ertl, Hildegund C J
Publicado 2022

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study

por Tannir, Nizar M, Cho, Daniel C, Diab, Adi, Sznol, Mario, Bilen, Mehmet A, Balar, Arjun V, Grignani, Giovanni, Puente, Erika, Tang, Lily, Chien, David, Hoch, Ute, Choudhury, Arkopal, Yu, Danni, Currie, Sue L, Tagliaferri, Mary A, Zalevsky, Jonathan, Siefker-Radtke, Arlene O, Hurwitz, Michael E
Publicado 2022

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma

por Diab, Adi, Tykodi, Scott S., Daniels, Gregory A., Maio, Michele, Curti, Brendan D., Lewis, Karl D., Jang, Sekwon, Kalinka, Ewa, Puzanov, Igor, Spira, Alexander I., Cho, Daniel C., Guan, Shanhong, Puente, Erika, Nguyen, Tuan, Hoch, Ute, Currie, Sue L., Lin, Wei, Tagliaferri, Mary A., Zalevsky, Jonathan, Sznol, Mario, Hurwitz, Michael E.
Publicado 2021